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The renal benefits of a healthy lifestyle. Over the next decade,
the number of patients with end-stage renal disease requiring
treatment by dialysis may double, and even developed nations
will have difficulty coping with this alarming increase. There is
an urgent need to highlight the importance of modifiable risk
factors as a basis for treatment strategies to prevent the devel-
opment and progression of chronic kidney disease (CKD). This
should include active extension of our current understanding of
a healthy lifestyle.
Obesity has become an international epidemic, and al-
tering this epidemic by changing lifestyle factors is crucial
to health and to the prevention of kidney disease today
and in the future. Alcohol may have beneficial effects
on renal function similar to those associated with cardio-
vascular disease; however, alcohol consumption is also a
potential risk factor for the development of glomerular
damage, hypertension, and hypertensive nephrosclero-
sis. In patients with diabetes, smoking increases the risk
of developing nephropathy and progressing to end-stage
renal failure. Smoking also reduces renal function and
increases albuminuria or proteinuria in the general pop-
ulation. Dietary salt intake affects renal function through
its effects on blood pressure and fibrosis, possibly via tu-
mor growth factor-b1–dependent pathways, suggesting
that excessive salt intake may be an important direct
pathogenic factor for cardiovascular and renal disease.
Exercise reduces resting blood pressure and prevents
abnormal increases in blood pressure during physical ex-
ertion. Modest weight loss through diet and physical ac-
tivity reduces the incidence of type 2 diabetes in high-risk
persons. The economic burden imposed by the costs of
dialysis and the high mortality related to CKD presents
a compelling argument for implementing a cost-effective
preventive strategy against end-stage renal disease. To
prevent CKD, recommendations about a healthy lifestyle
aimed at the individual should be consistent with public
health recommendations.
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CHRONIC KIDNEY DISEASE AS AN EPIDEMIC
PROBLEM
The worldwide increase in the number of patients with
chronic kidney disease (CKD) and consequent end-stage
renal disease (ESRD) requiring renal replacement ther-
apy is threatening to reach epidemic proportions over the
next decade. ESRD has a profound effect on morbidity,
mortality, and quality of life, and imposes a substantial
burden on health care expenditure [1]. The epidemic in-
crease in the incidence of ESRD in many countries high-
lights the importance of the modifiable risk factors as a
basis for devising treatment strategies to prevent the de-
velopment and progression of CKD.
Efforts to control the epidemic of CKD and its car-
diovascular complications have traditionally focused on
pharmacologic treatment of diabetes, hypertension, the
lipid profile, and proteinuria [2]. CKD prevention and
control strategies include defining at-risk populations and
elucidating potential targets for intervention. This should
include active extension of our current understanding of
health care and socioeconomic risk factors.
OBESITY
Obesity has become an international epidemic, and
there is growing agreement that certain lifestyle factors
are driving this epidemic. The modern lifestyle tends
to encourage overconsumption and discourages expen-
diture of energy. Minor gaps in the balance of energy
consumption and expenditure lead to gradual but steady
weight gain, and readdressing these trends is crucial to
health and to preventing kidney disease today and in the
future [3].
The metabolic syndrome, which is characterized by
obesity, insulin resistance, hyperinsulinemia, and dys-
lipidemia, might contribute to renal disease by many
pathways, including the development of type 2 diabetes,
hypertension, and cardiovascular disease. Obese patients
can develop proteinuria, which is followed by progres-
sive loss of renal function in a substantial proportion
of cases. Obesity-related glomerulopathy (ORG) is dis-
tinct from idiopathic focal and segmental glomeruloscle-
rosis (FSGS), and has a lower incidence of nephrotic
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Table 1. Percentage and mean (± standard deviation) of studied
parameters at baseline and 1 year after biliopancreatic diversion
Baseline One year P value
% HTA 61 12 <0.05
% Diabetes 20 0 <0.05
% Hyperlipidemia 24 10.7 0.1
Weight kg 128.9 ± 19 89.1 ± 14.9 <0.05
BMI kg/m2 47.6 ± 5.9 32.9 ± 4.9 <0.05
SBP mm Hg 138 ± 20 125.7 ± 15 <0.05
DBP mm Hg 82.9 ± 10 74.8 ± 9.4 <0.05
CrCl mL/min 152.3 ± 48.4 131.3 ± 59 <0.05
%Alb excretion >30 mg/day 25 0 <0.05
Abbreviations are: HTA, hypertension; BMI, body mass index; SBP, systolic
blood pressure; DBP, diastolic blood pressure; CrCl creatinine clearance; Alb,
albumin.
syndrome, more indolent course, consistent presence of
glomerulomegaly, and milder foot process fusion. The 10-
fold increase of ORG in incidence over the past 15 years
suggests a newly emerging epidemic [4]. Renal biopsies
and autopsy studies have shown that FSGS causes the
most common forms of histologic lesions in obese patients
with proteinuria. Considerable data show that hyperin-
sulinemia can mediate glomerular injury [5], although
glomerular hyperfiltration, hyperlipidemia, leptin, and
resistin, a hormone secreted by adipocytes, might also
be involved in the pathogenesis of FSGS associated with
obesity [6].
Weight loss decreases proteinuria in patients with
ORG. Praga et al studied a group of patients with obesity-
related proteinuria that was treated with hypocaloric di-
ets over 1 year, and reported a mean weight loss of 12%
and a decrease in proteinuria >80% [7]. In another study
of 30 overweight patients, a mean weight loss of 4% was
followed by a 31% decrease in proteinuria [8].
In general, being overweight is associated with a 2- to
6-fold increase in the risk of hypertension. Clinical trials
have also shown that weight loss is effective in the pri-
mary prevention of hypertension and in the reduction of
both systolic and diastolic blood pressure in patients with
normal or high blood pressure [9]. Decreasing the preva-
lence of obesity by improving lifestyle factors should help
in the primary prevention of CKD, particularly in devel-
oped countries. We prospectively studied a group of 35
morbidly obese patients (29 women and 6 men; mean
body mass index 47.6 ± 5.9 kg/m2) with obesity-related
proteinuria who had been treated by biliopancreatic
diversion. One year after surgery, weight loss was associ-
ated with significant decreases in hyperfiltration, microal-
buminuria, blood pressure, and the percentage of patients
with diabetes and hyperlipidemia (Table 1).
ALCOHOL
At present, epidemiologic studies have reported that
moderate alcohol and wine intake have protective effects
[10]. Alcohol may beneficially affect renal function via
similar mechanisms to those reported for cardiovascular
disease, such as by altering blood high-density lipopro-
teins, fibrinogen, insulin, and hemostatic factors. Burch-
fiel et al [11] found that alcohol intake was negatively
associated with an elevated degree of renal arteriolar
hyalinization, independent of other cardiovascular risk
factors at autopsy.
However, alcohol may have both positive and negative
effects on renal function. Alcohol consumption is a po-
tential risk factor for glomerular damage, hypertension,
and hypertensive nephrosclerosis [12]. In experimental
studies, alcohol-fed animals have significantly lower renal
function and more interstitial edema than their isocaloric
controls [13]. A case-control study based on self-reports
found that average consumption of more than 2 alcoholic
drinks per day was associated with an increased risk of
kidney failure in the general population [14]. In contrast,
a prospective study of 1658 nurses enrolled in the Nurses’
Health Study found no association between moderate al-
cohol consumption and rate of decline in renal function
[15].
SMOKING AS A RENAL RISK FACTOR
Diabetologists were the first to recognize the adverse
effects of smoking on the kidney. In people with ei-
ther type 1 or type 2 diabetes, smoking increases the
risk of developing nephropathy and nearly doubles the
rate of progression to end-stage renal failure [16]. Smok-
ing increases blood pressure, tachycardia, concentrations
of catecholamines, and renovascular resistance, which is
accompanied by decreases in glomerular filtration rate
(GFR) and filtration fraction. The effects of smoking are
presumed to be caused by nicotine itself because these
adverse effects are not associated with smoking nicotine-
free cigarettes [17]. In subjects without renal disease,
indirect evidence points to preferential afferent vasocon-
striction, which should protect the glomerular microcir-
culation against the rise in systemic blood pressure. In
contrast, in patients with primary renal disease, the acute
increase in blood pressure is not consistently accompa-
nied by afferent vasoconstriction. It has been argued
that in chronic smokers, compensatory activation of ni-
tric oxide–dependent vasodilation counteracts smoking-
induced vasoconstriction.
To investigate whether smoking is related to albumin-
uria and abnormal renal function in nondiabetic persons,
Pinto-Sietsma et al [18] studied 7476 participants in the
Prevention of Renal and Vascular End Stage Disease
Study. Current smokers (≤20 or >20 cigarettes/day) and
former smokers had increased median albumin excretion,
and were more likely to have high-normal albuminuria
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and microalbuminuria than nonsmokers. The percentage
of participants with an elevated GFR was lower in for-
mer smokers than in current smokers, and greater than
in nonsmokers. In contrast, the percentage of participants
with a decreased GFR was similar in former smokers and
nonsmokers and significantly lower in former smokers
than in current smokers.
In a retrospective case-control study of 4142 nondia-
betic participants 65 years of age or older in the Car-
diovascular Health Study Cohort study, Bleyer et al [19]
found that the number of cigarettes smoked per day pre-
dicted the decline in renal function. These data suggest
that quitting smoking could decrease the risk of renal in-
sufficiency in this older age group, which agrees with data
from a study of 455 adults in Minnesota that showed that
the decrease in creatinine clearance was greater in ex-
smokers and current smokers than in nonsmokers [20].
These studies suggest that smoking reduces renal function
and increases albuminuria or proteinuria in the general
population, an important problem from a public health
perspective.
Smoking is a powerful predictor of microalbuminuria
in patients with primary hypertension. The prevalence of
microalbuminuria in lean, hypertensive smokers is nearly
double that in nonsmokers [21]. In a prospective study
of factors predicting the loss of renal function, Regal-
ado et al [22] identified smoking as the most power-
ful predictor in patients with primary hypertension but
no evidence of primary renal disease. Smoking may ex-
plain at least part of the observation that patients with
primary hypertension show a progressive decline of re-
nal function despite adequate control of blood pressure
[23].
Cigarette smoking represents an important factor as-
sociated with the progression of nephropathy in patients
treated for hypertension and type 1 diabetes [16]. Cer-
tainly, there are many good reasons to stop smoking, par-
ticularly for diabetic patients. Sawicki et al [24] found
that patients with type 1 diabetes and nephropathy who
had good glycemic and blood pressure control and had
stopped smoking had significantly lower risk of progres-
sion than current smokers. Male patients with glomeru-
lonephritis [25] or atherosclerotic ischemic nephropathy
and who smoke [26] are at increased risk of impaired re-
nal function.
Kasiske et al [27] examined the prevalence and clinical
correlates of cigarette smoking in a large cohort of renal
transplant recipients. Compared with smoking less than
25 pack-years or having never smoked, smoking more
than 25 pack-years at transplantation was associated with
a 30% higher risk of graft failure and an increased risk of
death. The effects of smoking appear to dissipate 5 years
after quitting, suggesting that greater effort to encour-
age patients to quit smoking before transplantation may
decrease morbidity and mortality.
SALT INTAKE
The effect of salt on renal function is related to both
high blood pressure and to a direct effect on renal func-
tion. Hypertension is both a cause and consequence of
renal failure, but the precise nature and prevalence of
hypertensive nephrosclerosis as a cause of renal failure
remains controversial. There is strong evidence that hy-
pertension accelerates the progression of experimental
renal disease and that control of blood pressure helps pre-
vent this progression. The relation between blood pres-
sure and subsequent renal disease appears to be positive
and continuous throughout the full range of blood pres-
sure. In a 20-year community-based, prospective, obser-
vational study of the association between hypertension
on the future risk of CKD in 23,534 men and women,
Haroun et al found a strong graded relation between
CKD risk and the Sixth Report of the Joint National
Committee on Detection, Evaluation and Treatment of
High Blood Pressure criteria for blood pressure that was
equally strong in women as in men [28].
Although epidemiologic data show a direct relation be-
tween dietary sodium intake and blood pressure at the
population level, some experts question the universality
of the findings and oppose public health recommenda-
tions to decrease sodium intake in the general popula-
tion. Results from animal studies, epidemiologic studies,
and clinical trials have shown that a high intake of salt ad-
versely affects blood pressure. The DASH-Sodium trial
tested the effects on blood pressure of 3 levels of sodium:
higher (target of approximately 143 mmol/day, reflect-
ing typical U.S. consumption), intermediate (target of
106 mmol/day, reflecting the upper limit of current U.S.
recommendations), and lower (target of 65 mmol/day).
The data showed that reducing sodium intake decreased
blood pressure in participants with or without hyperten-
sion, which supports the current recommendations to
lower salt intake [29, 30].
A high salt intake may be relevant to the pathogene-
sis of essential hypertension and, independent of its hy-
pertensinogenic effects, may produce responses in the
kidney that lead to renal fibrosis, possibly via increased
renal production of tumor growth factor (TGF)-b . Yu
et al [31] reported the effect of a normal (1%) or high
(8%) sodium chloride diet on myocardial and renal fibro-
sis in spontaneously hypertensive rats and normotensive
Wistar-Kyoto rats. High dietary salt led to widespread fi-
brosis and increased TGF-b1 in the heart and kidney of
normotensive and hypertensive rats. These results sug-
gest that dietary salt has a specific effect on fibrosis,
possibly via TGF-b1–dependent pathways, and further
suggest that excessive salt intake may be an important
direct pathogenic factor for cardiovascular and renal dis-
ease. Such data reinforce the current guidelines to limit
salt intake to 6 g/day.
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PHYSICAL ACTIVITY
Sedentary behavior is one of the strongest risk fac-
tors for many chronic diseases and conditions, including
cardiovascular disease, hypertension, diabetes, obesity,
osteoporosis, colon cancer, renal disease, and depression.
A recent review of observational studies reported that the
risk for all-cause mortality was 20% to 30% lower among
adults who met the Healthy People 2010 recommenda-
tions (30 minutes of moderate activity for 5 or more days
per week or 20 minutes of vigorous activity 3 or more
times per week), and somewhat lower for adults who ex-
ercised moderately or vigorously at least a few times per
month or once per week [32].
Physical inactivity is a major risk factor for cardiovas-
cular disease, and persons who are less active or physi-
cally fit have a 30% to 50% greater risk for high blood
pressure. Together with diabetes mellitus, arterial hyper-
tension is the most important cause of renal failure and
dialysis in developed countries. The safety and efficacy
of mild to moderate exercise have significant positive
clinical implications for all hypertensive patients. The
exercise-induced reduction in resting blood pressure and
prevention of abnormal increases in blood pressure dur-
ing physical exertion reduces the risk of cardiovascular
events. These changes may also reduce the need for, and
the cost and side effects of, antihypertensive medication,
and may improve quality of life. A meta-analysis of re-
cent clinical trials has demonstrated that physical activity
reduces blood pressure in hypertensive and normoten-
sive persons independent of weight loss [33]. Therefore,
increasing aerobic physical activity should be considered
an important lifestyle modification to prevent and treat
high blood pressure.
Low physical fitness combined with obesity in aging
persons in developed countries promotes a number of
degenerative diseases, including CKD. Physicians often
recommend physical activity to patients with type 2 dia-
betes. Exercise can improve glycemic control and insulin
sensitivity, and may prevent the development of type 2
diabetes [34]. Compelling scientific evidence from ran-
domized, controlled trials conducted in 3 countries in-
dicates that a change in lifestyle prevents or delays the
occurrence of type 2 diabetes in high-risk groups [35].
This body of evidence has also definitively established
that modest weight loss through diet and physical activ-
ity reduces the incidence of type 2 diabetes in high-risk
persons by about 40% to 60% over 3 to 4 years [35].
CONCLUSION
Careful attention to metabolic and lifestyle issues may
help slow the loss of renal function. Strategies to intro-
duce and encourage a healthy lifestyle among our popu-
lation should become a priority.
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